FTC Sides With Amneal Over Inhaler Patent Dispute With Teva

In its continued effort to tackle improper patent listings, the US Federal Trade Commission has filed an amicus brief urging a US Court to remove Teva’s inhaler patents from the Food and Drug Administration’s Orange Book, as such siding with defendant Amneal.

The brief is related to a case that was brought by Teva against Amneal after the latter sought FDA approval for its generic version